Literature DB >> 22569265

Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1α in human umbilical vein endothelial cells.

Tomohiro Kozako1, Noriko Matsumoto, Yukako Kuramoto, Akira Sakata, Rie Motonagare, Akiyoshi Aikawa, Masumi Imoto, Akihisa Toda, Shin-ichiro Honda, Hiroshi Shimeno, Shinji Soeda.   

Abstract

Vasohibin is thought to be an important negative feedback regulator of angiogenesis that is selectively induced in endothelial cells by VEGF. Here, we assessed the role of vasohibin on HIF-1α expression under oxidative stress induced by hydrogen peroxide (H₂O₂) in HUVEC. VEGF induced significant cell growth that was associated with an increase in vasohibin expression. Following H₂O₂-pretreatment, VEGF further increased cell growth but this was contrastingly associated with a decrease in vasohibin expression when compared with VEGF alone. Interestingly, vasohibin inhibited cell proliferation through degradation of HIF-1α expression during H₂O₂-pretreatment. Furthermore, vasohibin elevated the expression of prolyl hydroxylase (PHD). These results suggest that vasohibin plays crucial roles as a negative feedback regulator of angiogenesis through HIF-1α degradation via PHD.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569265     DOI: 10.1016/j.febslet.2012.03.007

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

Review 2.  The vasohibin family: a novel family for angiogenesis regulation.

Authors:  Yasufumi Sato
Journal:  J Biochem       Date:  2012-10-25       Impact factor: 3.387

3.  Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma.

Authors:  Guangning Zhao; Yuming Yang; Yang Tang; Ruifa Han; Yan Sun
Journal:  Med Oncol       Date:  2012-08-03       Impact factor: 3.064

4.  TJ0711, a novel vasodilatory β-blocker, protects SHR rats against hypertension induced renal injury.

Authors:  Juan Yang; Yong Ning; Jun Qiu; Jin-Seng He; Wei Li; Zu-Fu Ma; Ju-Fang Shao; Yue-Qiang Li; Rui Zeng; Meng Zhang; Jia Cheng; Su-Fang Chen; Gang Xu; Cong-Yi Wang; Ying Yao
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 5.  Antiangiogenic Therapy for Diabetic Nephropathy.

Authors:  Katsuyuki Tanabe; Yohei Maeshima; Yasufumi Sato; Jun Wada
Journal:  Biomed Res Int       Date:  2017-08-01       Impact factor: 3.411

6.  Genetic Deletion of Vasohibin-2 Exacerbates Ischemia-Reperfusion-Induced Acute Kidney Injury.

Authors:  Hiromasa Miyake; Katsuyuki Tanabe; Satoshi Tanimura; Yuri Nakashima; Tomoyo Morioka; Kana Masuda; Hitoshi Sugiyama; Yasufumi Sato; Jun Wada
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 7.  Alternative Splicing in Angiogenesis.

Authors:  Elizabeth Bowler; Sebastian Oltean
Journal:  Int J Mol Sci       Date:  2019-04-26       Impact factor: 5.923

8.  Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review).

Authors:  Qian-Ru Tao; Ying-Ming Chu; Lan Wei; Chao Tu; Yuan-Yuan Han
Journal:  Mol Med Rep       Date:  2021-02-08       Impact factor: 2.952

Review 9.  The roles of vasohibin and its family members: Beyond angiogenesis modulators.

Authors:  Hua Du; Jing Zhao; Ling Hai; Jing Wu; Hua Yi; Yonghong Shi
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.